We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Swiss biopharmaceutical firm Neurimmune has partnered with German biotechnology company Ethris to develop mRNA-based, neutralising antibodies for a Covid-19 therapeutic formulated for inhalation.